OSR Holdings, Inc. (NASDAQ:OSRH) Short Interest Update

OSR Holdings, Inc. (NASDAQ:OSRH) was the recipient of a large drop in short interest during the month of December. As of December 31st, there was short interest totaling 544,307 shares, a drop of 37.6% from the December 15th total of 872,385 shares. Approximately 5.4% of the company’s shares are sold short. Based on an average trading volume of 471,049 shares, the days-to-cover ratio is currently 1.2 days. Based on an average trading volume of 471,049 shares, the days-to-cover ratio is currently 1.2 days. Approximately 5.4% of the company’s shares are sold short.

OSR Price Performance

OSRH stock traded down $0.03 during mid-day trading on Friday, reaching $0.75. The company had a trading volume of 1,252,668 shares, compared to its average volume of 2,787,571. The company has a market capitalization of $19.18 million, a PE ratio of -0.67 and a beta of 1.42. The firm has a 50 day moving average of $0.63 and a 200 day moving average of $0.71. OSR has a 12 month low of $0.45 and a 12 month high of $12.54.

OSR (NASDAQ:OSRH) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $0.63 million during the quarter.

Institutional Trading of OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP bought a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned approximately 0.37% of OSR at the end of the most recent reporting period. Institutional investors and hedge funds own 55.30% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Wall Street Zen upgraded shares of OSR to a “sell” rating in a report on Saturday, October 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.